4 April 2022 - Targeting both cancer driving and resistance mechanism pathways, Rybrevant offers a unique treatment approach for an underserved patient population.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance with Conditions approving Rybrevant (amivantamab), a fully-human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.

Read Janssen press release